By Fineline Cube 
Suzhou Forlong Biotechnology Co., Ltd. announced that FL115 subcutaneous injection (administered once every three weeks) has been approved to initiate a Phase 1 clinical study in Australia for patients with advanced solid tumors.
Clinical Development Milestone
| Item | Detail |
|---|---|
| Company | Suzhou Forlong Biotechnology Co., Ltd. |
| Product | FL115 subcutaneous injection |
| Dosing Schedule | Once every three weeks |
| Indication | Advanced solid tumors |
| Trial Phase | Phase 1 |
| Location | Australia |
| Approval Date | 4 Aug 2026 |
Drug Profile & Mechanism of Action
- Molecule Type: Engineered IL-15/IL-15Rα-Fbody fusion protein
- Primary Function: Enhances anti-tumor immune activity of NK cells and CD8+ T cells through IL-15-mediated signaling pathways
- Innovation: Significantly minimizes complex effects introduced by the Fc region
- Previous Clinical Experience: Already evaluated as monotherapy via intravenous infusion in two Phase I clinical studies in patients with advanced solid tumors
- Development Status: Demonstrated favorable safety profile and preliminary clinical efficacy with potential to be “best-in-class” therapy
Strategic Significance
The approval to initiate clinical trials in Australia represents a significant milestone in Forlong Bio’s global development strategy. Subcutaneous administration offers several advantages over traditional intravenous delivery:
- Improved patient convenience and quality of life
- Reduced treatment burden and healthcare resource utilization
- Potential for home-based administration in later development stages
- Enhanced compliance through simplified dosing schedule
Market Opportunity & Competitive Landscape
- Global Solid Tumor Burden: Represents the majority of cancer diagnoses worldwide with significant unmet medical needs
- Current Treatment Limitations: Many patients develop resistance to existing therapies or experience significant toxicity
- Competitive Positioning: FL115’s engineered design to minimize Fc region effects differentiates it from other IL-15 based therapies
- Commercial Potential: Successful development could position Forlong Bio as a leader in next-generation immuno-oncology therapeutics
Company Pipeline Strategy
“This approval enables us to advance our novel therapeutic candidate into human testing, bringing us closer to potentially addressing unmet needs in oncology,” said a Forlong Bio spokesperson. “FL115 represents our commitment to developing differentiated treatments that improve patient outcomes through innovative delivery mechanisms.”
Forlong Bio expects to report preliminary safety data from the Phase 1 trial within the next 12-18 months, which could inform subsequent development decisions and potential expansion into additional indications.
Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical development timelines, regulatory pathways, and commercial expectations for FL115. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market adoption.-Fineline Info & Tech